J. Greg Slatter

2.9k citations

50 papers · 1.9k indexed · h-index 21

Impact in

Pharmacology top 0.5%
- Pharmacogenetics and Drug Metabolism
- Drug-Induced Hepatotoxicity and Protection
Oncology top 5%
- Drug Transport and Resistance Mechanisms

Papers in

Pharmacology 18
- Pharmacogenetics and Drug Metabolism 18
- Drug-Induced Hepatotoxicity and Protection 5
Genetics 15
- Chronic Lymphocytic Leukemia Research 14

Co-authors: Thomas A. Baillie Larry C. Wienkers Leslie J. Dickmann Sonal Patel Paul G. Pearson James P. Sams Larry J. Schaaf Roger G. Ulrich
Journals: Xenobiotica (8 papers)Drug Metabolism and Disposition (7 papers)Journal of Clinical Oncology (4 papers)The Journal of Clinical Pharmacology (3 papers)Chemical Research in Toxicology (3 papers)
Partner nations: United States Japan United Kingdom

In The Last Decade

J. Greg Slatter

49 papers receiving 1.9k citations

Peers

Countries citing papers authored by J. Greg Slatter

Since Specialization

Citations

This map shows the geographic impact of J. Greg Slatter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Greg Slatter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Greg Slatter more than expected).

Fields of papers citing papers by J. Greg Slatter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Greg Slatter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Greg Slatter. The network helps show where J. Greg Slatter may publish in the future.

Co-authors

The 25 scholars most cited alongside J. Greg Slatter, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with J. Greg Slatter Line = papers co-authored together J. Greg Slatter links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Identification and Characterization of ACP-5862, the Major Circulating Active Metabolite of Acalabrutinib: Both Are Potent and Selective Covalent Bruton Tyrosine Kinase Inhibitors Journal of Pharmacology and Experimental Therapeutics ·Terry Podoll, Paul G. Pearson, Allard Kaptein, Jerry Evarts, Gerjan de Bruin, Scott Van Zant, Anouk de Jong, Bart van Lith, Hao Sun, Stephen J. Byard, Adrian J. Fretland, Handayani Lubis Sri, Tjeerd Barf, J. Greg Slatter	2022	15
2	Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies Clinical Pharmacokinetics ·A.A. Mirzaians, 刘素林, Graham R. Kimber, J. Greg Slatter, Sergey Aksenov, Nidal Al‐Huniti	2018	17
3	Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans Drug Metabolism and Disposition ·Terry Podoll, Paul G. Pearson, Jerry Evarts, Saulo Amaral Carminati, Елена Бибикова, Hao Sun, Mark Gohdes, ميساء عبد القادر, Mitesh Sanghvi, J. Greg Slatter	2018	50
4	Pharmacokinetics, Biotransformation, and Excretion of [14C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis Clinical Pharmacokinetics ·Raju Subramanian, Xiaochun Zhu, M. Benjamin Hock, Weichneg Xu, Benjamin Wu, Yuhang Zhang, Ogo Egbuna, J. Greg Slatter, Jim Xiao, Gary L. Skiles	2016	21
5	Therapeutic Protein Drug–Drug Interactions: Navigating the Knowledge Gaps–Highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA Workshop The AAPS Journal ·Jane R. Kenny, Cecilly Golden, Andrew Chow, Justin Earp, Raymond Evers, J. Greg Slatter, Diane D. Wang, Lei Zhang, Honghui Zhou	2013	33
6	Regiospecific and Stereospecific Triangulation of the Structures of Metabolites Formed by Sequential Metabolism at Multiple Prochiral Centers Drug Metabolism and Disposition ·Robert J. Greene, John A. Davis, Raju Subramanian, S. Katoh, Maurice G. Emery, J. Greg Slatter	2012	4
7	Activity-based exposure comparisons among humans and nonclinical safety testing species in an extensively metabolized drug candidate Xenobiotica ·Xiaochun Zhu, J. Greg Slatter, Maurice G. Emery, S. Katoh, Anna Akrami, Xiping Zhang, Dean Hickman, Gary L. Skiles, Raju Subramanian	2012	3
8	Effects of Interleukin 1β (IL-1β) and IL-1β/Interleukin 6 (IL-6) Combinations on Drug Metabolizing Enzymes in Human Hepatocyte Culture Current Drug Metabolism ·Leslie J. Dickmann, Sonal Patel, Larry C. Wienkers, J. Greg Slatter	2012	62
9	Effects of Interleukin-6 (IL-6) and an Anti-IL-6 Monoclonal Antibody on Drug-Metabolizing Enzymes in Human Hepatocyte Culture Drug Metabolism and Disposition ·Leslie J. Dickmann, Sonal Patel, Dan A. Rock, Larry C. Wienkers, J. Greg Slatter	2011	145
10	Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222 Xenobiotica ·Robert J. Greene, Hua Tu, John P. Gibbs, J. Greg Slatter	2011	9
11	Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver Genome Research ·Xia Yang, Bin Zhang, Cliona Molony, Eugene Chudin, Ke Hao, Jun Zhu, Andrea Gaedigk, Christine Suver, Hua Zhong, J. Steven Leeder, F. Peter Guengerich, Stephen C. Strom, Erin G. Schuetz, Thomas H. Rushmore, Roger G. Ulrich, J. Greg Slatter, Eric E. Schadt, Andrew Kasarskis, Pek Yee Lum	2010	207
12	Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements Xenobiotica ·R. Foti, Leslie J. Dickmann, John A. Davis, Robert J. Greene, John J. Hill, Monique Howard, Josh T. Pearson, Dan A. Rock, MAGNANI M.C.A.O., Jan L. Wahlstrom, J. Greg Slatter	2008	45
13	In Vitro Metabolic Activation of Lumiracoxib in Rat and Human Liver Preparations Drug Metabolism and Disposition ·Ying Li, J. Greg Slatter, Zhoupeng Zhang, Yan Li, George A. Doss, Matthew P. Braun, Ralph A. Stearns, Dennis Dean, Thomas A. Baillie, Wei Tang	2007	34
14	Advances in predicting CYP-mediated drug interactions in the drug discovery setting Expert Opinion on Drug Discovery ·Jan L. Wahlstrom, Dan A. Rock, J. Greg Slatter, Larry C. Wienkers	2006	7
15	Pharmacokinetics, Metabolism, and Excretion of Irinotecan (CPT-11) Following I.V. Infusion of [14C]CPT-11 in Cancer Patients Drug Metabolism and Disposition ·J. Greg Slatter, Larry J. Schaaf, James P. Sams, Kenneth L. Feenstra, 誠牛膓, Paul A. Bombardt, K. S. Cathcart, Farah Zafar, Laura Pearson, Linda D. Compton, Langdon L. Miller, David Baker, 海月, Raymond S. Lord	2000	241
16	Venous irritation, pharmacokinetics, and tissue distribution of tirilazad in rats following intravenous administration of a novel supersaturated submicron lipid emulsion. Pharmaceutical Research ·Youmin Wang, Shekhar R. Inamke, C. Rodríguez, J. Greg Slatter, Hugh Caspe, Kanchan Wankhede, Michael J. Higgins	1999	19
17	Biotransformation of methyl isocyanate in the rat. Evidence for glutathione conjugation as a major pathway of metabolism and implications for isocyanate-mediated toxicities Chemical Research in Toxicology ·J. Greg Slatter, Mohamed S. Rashed, Paul G. Pearson, Swapna Nama, Thomas A. Baillie	1991	89
18	Carbamoylation of peptides and proteins in vitro by S-(N-methylcarbamoyl)glutathione and S-(N-methylcarbamoyl)cysteine, two electrophilic S-linked conjugates of methyl isocyanate Chemical Research in Toxicology ·Paul G. Pearson, J. Greg Slatter, Mohamed S. Rashed, Nafiseh Talaei, Thomas A. Baillie	1991	47
19	In Vitro and in Vivo Investigations of Dihydropyridine-Based Chemical Delivery Systems for Anticonvulsants Pharmaceutical Research ·Alan V. Boddy, Salas Cazon, F. Lepage, Luis Fernando Paguana, J. Greg Slatter, Thomas A. Baillie, René H. Levy	1991	8
20	S-(N-Methylcarbamoyl)glutathione: A reactive S-linked metabolite of methyl isocyanate Biochemical and Biophysical Research Communications ·Paul G. Pearson, J. Greg Slatter, Mohamed S. Rashed, Intan Karilla Bumanda, Mark P. Grillo, Thomas A. Baillie	1990	52

About J. Greg Slatter

J. Greg Slatter is a scholar working on Pharmacology, Genetics, Biochemistry, Pathology and Forensic Medicine and Oncology, having authored 50 papers that have together received 1.9k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (18 papers), Chronic Lymphocytic Leukemia Research (14 papers), Lymphoma Diagnosis and Treatment (11 papers), PI3K/AKT/mTOR signaling in cancer (7 papers), Computational Drug Discovery Methods (7 papers), Drug Transport and Resistance Mechanisms (6 papers), Drug-Induced Hepatotoxicity and Protection (5 papers) and Sulfur Compounds in Biology (5 papers). The work is most often cited by research in Pharmacology (540 citations), Oncology (666 citations), Biochemistry (126 citations), Genetics (162 citations) and Pharmaceutical Science (75 citations). J. Greg Slatter has collaborated with scholars based in United States, Japan and United Kingdom. Frequent co-authors include Thomas A. Baillie, Larry C. Wienkers, Leslie J. Dickmann, Sonal Patel, Paul G. Pearson, James P. Sams, Larry J. Schaaf, Roger G. Ulrich, Mohamed S. Rashed and Dan A. Rock. Their work appears in journals such as Xenobiotica, Drug Metabolism and Disposition, Journal of Clinical Oncology, The Journal of Clinical Pharmacology and Chemical Research in Toxicology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact